Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another. METHODS: We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care settings. The primary outcome was symptom remission, defined by a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of the study. Scores on the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR-16), obtained at treatment visits, determined secondary outcomes, including remission (a score of 5 or less at exit) and response (a reduction of 50 percent or more on baseline scores). RESULTS: Remission rates as assessed by the HRSD-17 and the QIDS-SR-16, respectively, were 21.3 percent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline, and 24.8 percent and 25.0 percent for extended-release venlafaxine. QIDS-SR-16 response rates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent for extended-release venlafaxine. These treatments did not differ significantly with respect to outcomes, tolerability, or adverse events. CONCLUSIONS: After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant. Any one of the medications in the study provided a reasonable second-step choice for patients with depression. (ClinicalTrials.gov number, NCT00021528.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A subset of those suffering from Major Depressive Disorder (MDD) achieve remission with antidepressant medication (ADM)1.”
From The relationship between resting-state functional connectivity, antidepressant discontinuation and depression relapse (2020) · cites this paper as [1]
In the citing paper
“about onethird receive no benefit from two or more pharmacologic treatments (Rush et al., 2006;Trivedi et al., 2006).”
From Neurocognitive effects of theta burst stimulation for treatment-resistant depression in adults: A systematic review and recommendations for future research (2025) · cites this paper as Rush et al., 2006
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Schafer, J. L. (1999) · Statistical Methods in Medical Research · doi:10.1177/096228029900800102 · Cited by 3,949
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Self-citationRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Self-citationCUMULATIVE ILLNESS RATING SCALE
LINN, B. S., LINN, M. W., & GUREL, L. (1968) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1968.tb02103.x · Cited by 2,304
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Self-citationAgency for Health Care Policy and Research
Eisenberg, J. M. (1999) · Medical Care · doi:10.1097/00005650-199903000-00001 · Cited by 1,369
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
Self-citationMedication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Self-citation
Research works printed but not linked: 4
- Agency for Health Care Policy and Research. Depression in primary care. Vol. 2. Treatment of major depression. Rockville, Md.: Department of Health and Human Services, 1993. (AHCPR publication no. 93-0551.)
- Fava M, 2000, J Clin Psychiatry, 61, 10
- Joffe RT, 1996, J Clin Psychiatry, 57, 114
- Fava M, 2003, Ann Clin Psychiatry, 15, 17, 10.3109/10401230309085666 · doi:10.3109/10401230309085666 · Paper page
Cited by
Items 901–999 of 999
Mokhber, N., & Talaeı, A. (2007)
Ask the Expert P sychopharmacology : M ajor depressive disorder
Zisook, S. (2006) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.4.4.484
Valenstein, M. (2006) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.4.4.522
Correlation study of SSRIs drugs in Sexual Dysfunction
Moghadamnia, M., Nabavi, S. M., & Afshin‐Majd, S. (2013)
Lo, V., & Maggio, L. A. (2010) · PubMed
Stotland, N. L. (2006) · Journal watch · doi:10.1056/wh200605020000008
Therapeutic Neuromodulation: Clinical and Research Implications of a New Therapeutic Platform
(2007) · Psychiatric Annals · doi:10.3928/00485713-20070301-02 · Cited by 1
Malone, D. C., & Tierney, J. G. (2007) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2007.13.s6-a.1
“Another study comparing citalopram with escitalopram was conducted by Hemels et al.32 This analysis was conducted from an Austrian societal and Social Healthcare Insurance System perspective using a 6-month time frame.”
BackgroundResultInfluentialDesvenlafaxine for depression.
Lincoln, J., & Preskorn, S. (2008) · PubMed
Ali, L. (2013) · HEC National Digital Library
Hispanic Outpatients in STAR ∗ D
Lesser, I. M., Zisook, S., Flores, D. L., Sciolla, A., Wisniewski, S. R., Epstein, M., Rosales, A., Luther, J. F., & Rush, A. J. (2008)
Self-citationWas tun, wenn die antidepressive Behandlung versagt?
Schmauß, M. (2012) · NeuroTransmitter · doi:10.1007/s15016-012-0084-9
Roosevelt, T. (2006)
ACMDCouncil on the Misuse of Drugs
Sulaiman, Z., Street, M., & Featherstone, L. (2014)
1. Current Development of Novel Medicinal Products for Major Depressive Disorder
Nakabayashi, T. (2012) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.43.131
Multiple Levels of Drug Treatment for Depression
Brett, A. S. (2006) · Journal watch · doi:10.1056/jd200605230000009
What to Do After Depressed Patients Fail an SSRI
Roy‐Byrne, P. (2006) · Journal watch · doi:10.1056/jp200604050000001
Taylor, M. A., & Fink, M. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970903101715
“The lack of diagnostic reliability of the present diagnostic systems is clearly reflected in the poor outcomes of the large national multi-site trials of antidepressant and antipsychotic agents (Lieberman et al. 2005; Rush et al. 2006a).”
ResultAlgorithms: STAR*D, Positives, Negatives, and Implications for Clinical Practice
Huynh, N., & McIntyre, R. S. (2009) · doi:10.3109/9781420084887-7
Outcomes in the Treatment of Major Depressive Disorder
Thase, M. E., & Koenig, A. M. (2009) · doi:10.3109/9781420084887-4
Self-citationPharmacological Approaches to Treatment-Resistant Depression
Fava, M., & Nierenberg, A. A. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04743-2.50046-9
Self-citationDEPRESSION AND BIPOLAR DISORDERS
Berrettini, W. H. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50057-3
Individualized Treatment of Depression
(2013) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814343664_0010
Whitaker, R., & Cosgrove, L. (2015) · Palgrave Macmillan US eBooks · doi:10.1057/9781137516022_7
Psychopharmacology of mood disorders
Coryell, W. H., & Geddes, J. R. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544392.029
Tratamento medicamentoso da depressão maior refratária
Rocha, F. L., Hara, C., & Barbosa, I. G. (2016) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Gene expression dysregulation in medication refractory depression
Iacob, E. (2019) · J. Willard Marriott Library · doi:10.26053/0j-c3nm-4ep8
Rosenfeld, J. A. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511642111.021
Repetitive Transcranial Magnetic Stimulation in Major Depression
Braga, H. A., Freire, Á. M., Saraiva, A. D. O., Moreira, A. C., da Silva, F. C. T., & Neto, M. L. R. (2016) · Journal of Neurology and Neuroscience · doi:10.21767/2171-6625.1000150
“After acute-phase pharmacotherapy, psychotherapy, or both, most depressed patients either do not improve or achieve only partial symptomatic improvement [7-12].”
Serafini, G., Hayley, S. P., Ghasemi, M., & Amore, M. (2017) · Wiley eBooks · doi:10.1002/9783527803781.ch11
Chronische und therapieresistente Depressionen (ICD-10 F3)
Schramm, E., Bauer, M., & Adli, M. (2013) · Elsevier eBooks · doi:10.1016/b978-3-437-24904-4.00011-2
Recent Advances in the Management of Major Depression: An Evidence-Based Approach
Rush, A. J., Jo, B., Distinguished, H., & Aurora, M. (2007)
Self-citationFuture Perspectives on Immune-Related Treatments
Baune, B. T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811073-7.00035-0
Neuroimmunopharmacology at the Interface of Inflammation and Pharmacology Relevant to Depression
Holmes, J., Corrigan, F., & Hutchinson, M. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811073-7.00012-x
Brazill, K., Warnick, S. J., & White, C. (2018) · The International Journal of Psychiatry in Medicine · doi:10.1177/0091217418791434
Implications of Pharmacogenomics in Depression Pathophysiology and Treatment
Forbes, M., Jaksa, P., Eyre, H. A., & Bousman, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813333-0.00030-5
Use of Buprenorphine in Treatment Resistant Depression
Khan, A. (2018) · Open Access Journal of Toxicology · doi:10.19080/oajt.2018.03.555611
“Therapeutic strategies such as such as switching antidepressants and using adjuvant drug treatment have improved the condition but in 40 percent of cases patients remain symptomatic and fail to achieve full remission [4,5].”
BackgroundPharmacoepigenetics of Major Depression
Fries, G. R., Eyre, H. A., Bousman, C., Quevedo, J., & Baune, B. T. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813939-4.00027-9
Community Psychological Practice and a Note on Rehabilitation in Corrections
EPSTEIN, W. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-32750-7_9
García–Parés, G., Pérez‐Blanco, J., Sánchez-Pérez, M., Roncero, C., Foras, F., Gálvez, V., Cardoner, N., Crespo-Blanco, J. M., & Navarro-Odriozola, V. (2011) · Actas Españolas de Psiquiatría
Stimulation magnétique transcrânienne répétitive
Gharib, A. M., Haesebaert, F., & Poulet, E. (2019)
Bauer, M., Monz, B. U., Montejo, A. L., Quail, D., Dantcheve, N., Demyttenaere, K., Garcia-Cebrian, A., Grassi, L. G., David, P., Reed, C. C., et al. (2008) · European psychiatry (Ed Española) · doi:10.1017/s1134066500005774
Brief Review of Major Depressive Disorder for Primary Care Providers.
Jj, C., & Escalona, P. R. (2016) · Europe PMC (PubMed Central)
McLaughlin, P., & Cleare, A. J. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.009
Sex-specific retinal anomalies induced by chronic social stress in micePreprint
Arsenault, E., Lavigne, A.-A., Mansouri, S., Francis, K., Bittar, T. P., Quessy, F., Abdallah, K., Barbeau, A., Hébert, M., & Labonté, B. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.28.317230
Kverno, K. S. (2020) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20201210-03 · Cited by 1
“…of specifi c mental disorders, and the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial results remind us that remission of symptoms may be a process that takes time and may involve a trial of more than one medication or augmentation (Rush et al., 2006; Trivedi et al., 2006).”
BackgroundMissing the Diagnosis Altogether
Josephs, K. A., Rodriguez‐Porcel, F. E., Shatz, R. S., Weintraub, D. A., & Espay, A. J. (2020)
“Memory Is So Good She Will Never Get Dementia”
Josephs, K. A., Rodriguez‐Porcel, F. E., Shatz, R. S., Weintraub, D. A., & Espay, A. J. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108355841.005
Blier, P. (2007) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0722
Combination Therapies and Switching of Agents in Depression and Bipolar Disorders
Folsche, T., Maier, H. B., Hillemacher, T., & Frieling, H. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_437-1 · Cited by 1
Can hormones get you down? studies on sex steroids and depression
de Wit, A. E. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.178483963 · Cited by 1
(2008) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000326890.56044.55
Type 2 Diabetes and Psychiatry
Calcia, M., Whicher, C. A., Price, H. C., Ismail, K., & Moulton, C. D. (2022) · doi:10.1093/med/9780198870197.003.0274
(2010) · Wiley eBooks · doi:10.1002/9780470689394.refs
Joel Paris, M. D. (2010) · Wiley eBooks · doi:10.1002/9780470666630.refs
Finley, P. R., Lê, J., & Lee, K. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-27883-4_9 · Cited by 1
Holsboer‐Trachsler, E., & Holsboer, F. (2008) · Springer eBooks · doi:10.1007/978-3-540-68748-1_28 · Cited by 1
Laux, G. (2011) · Springer eBooks · doi:10.1007/978-3-642-03637-8_55
Een depressie die niet geneest met een SSRI. Wat nu?
(2006) · Huisarts en Wetenschap · doi:10.1007/bf03084800
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372997.as03 · Cited by 1
Laux, G. (2008) · Springer eBooks · doi:10.1007/978-3-540-33129-2_55
Algorithms: STAR*D, Positives, Negatives, and Implications for Clinical Practice
Huynh, N., & McIntyre, R. S. (2009) · Medical psychiatry · doi:10.3109/9781420084887.005
Drake, K., Bess, J. D., & Casher, M. I. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108656672.004 · Cited by 1
Bibliography for Major Depressive Disorder and Suicide
(2008) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.6.1.foc58
Gonda, X. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736827892.793567833
Gysling, E. (2006) · pharma-kritik · doi:10.37667/pk.2005.133
&NA; (2011) · Drugs & Therapy Perspectives · doi:10.2165/11207880-000000000-00000
Evidenzbasierung und leitliniengestützte Therapie in der Psychiatrie
Möller, H. (2007) · Springer eBooks · doi:10.1007/978-3-540-33129-2_41
Deep Brain Stimulation for Highly Refractory Depression
Dougherty, D. D., Widge, A. S., & Greenberg, B. D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-805353-9.00087-5
Krupnik, V. (2017) · Journal of EMDR Practice and Research · doi:10.1891/1933-3196.11.1.1
Haggerty, J. J., & Sickel, M. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4417-8.50171-6
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372300.as03
Unmet Needs in the Management of Major Depressive Disorder
(2010) · CNS Spectrums · doi:10.1017/s1092852900027929
Ontiveros, J. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82568
“In another study, 477 patients resistant to an SSRI treated for 14 weeks with bupropion SR (average dose 238 mg/day) or sertraline (average dose 136 mg/day) remission was achieved on 21 and 18% of the subjects, respectively [57].”
New Developments in the Treatment of Depression with tDCS
Moffa, A. H., Martin, D. M., & Loo, C. K. A. (2022) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780198832256.013.37
Tokarzewska, A., Orczyk, J., OŁOWNIA, A., & Małyszek, M. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.13.05.002
Combined Psychotherapy and Somatic Treatments
Teo, D. C. L., Silvio, J. R., Condemarín, R., Nair, S. S., Alfonso, C. A., & Tasman, A. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_95-1
Early Intervention Across Mental Health Services
Brown, E., Stainton, A., Chanen, A. M., Davey, C. G., Bedi, G., & McGorry, P. D. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_171-1
Rethorst, C. D., Trombello, J. M., Chen, P. M., Carmody, T. J., Goodman, L. C., Lazalde, A., & Trivedi, M. H. (2023) · doi:10.2196/preprints.54479
Self-citationStevenson, K. A., Hamilton, D. V., & Clayton, A. H. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as18
(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551289.cd03 · Cited by 1
Combined Psychotherapy and Somatic Treatments
Teo, D. C. L., Silvio, J. R., Condemarín, R., Nair, S. S., Alfonso, C. A., & Tasman, A. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_95
Early Intervention Across Mental Health Services
Brown, E., Stainton, A., Chanen, A. M., Davey, C. G., Bedi, G., & McGorry, P. D. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_171 · Cited by 1
Dilweg, M. A., Mocking, T. A. M., Maragkoudakis, P., van Westen, G. J. P., Heitman, L. H., IJzerman, A. P., Jespers, W., & van der Es, D. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00521j · Cited by 1
[Erratum] Brain Imaging and neurostimulation in health and disorders: status report
Baptista, A. F., Casali, A. G., Oda, A. L., Okano, A. H., Moreira, A., Santos, A. L. Y. D. S., Fernandes, A. M., Fontana, A. P., Brunoni, A. R., Fonseca, A. R. O., et al. (2024) · Brain Imaging and Stimulation · doi:10.17267/2965-3738bis.2024.e5952
Gründer, G. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21199-7.00002-7
Lee, D. Y., Park, R. W., & Jeon, S. M. (2025) · European Psychiatry · doi:10.1192/j.eurpsy.2024.1815 · Cited by 2
“The Sequenced Treatment Alternatives to Relive Depression (STAR*D) trial reported that bupropion was an effective augmenting agent for TRD [12, 13].”
Current Treatments for Depression
Fava, M., & Krystal, J. H. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197640654.003.0034
Missing a trick? Bupropion for the pharmacological treatment of depression in the UK
Browning, M. D., & Cowen, P. J. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2025.50
Ding, J., Chen, Y., Zhang, Y., zhang, S., Li, L., Xing, H., & Zhai, Y. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120487
Pharmacoepigenetics of major depression
Baune, B. T., & Assche, E. V. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-18722-3.00007-4
Aadland, H., Hirst, C., Charbonneau, E. F., Chowdhury, M., & Chivers-Wilson, K. (2025) · Journal of Military Veteran and Family Health · doi:10.3138/jmvfh-2023-0093
Metadata
- Authors
- Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., Shores-Wilson, K., Niederehe, G., & Fava, M.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- University of Pittsburgh (US)
- New York State Psychiatric Institute (US)
- Massachusetts General Hospital (US)
- National Institute of Mental Health (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-03-23
- Volume
- 354
- Issue
- 12
- Pages
- 1231-1242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140787893
- Cited by
- 1,033
- References
- 44
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 30 · 2023: 30 · 2022: 28 · 2021: 46 · 2020: 43 · 2019: 54 · 2018: 51 · 2017: 35 · 2016: 42 · 2015: 45 · 2014: 46 · 2013: 45 · 2012: 43
- FWCI
- 66.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01mh90003-26-0-0)
- National Institute of Mental Health (N01‐MH‐90003)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- major depressive disorder, antidepressant switching, bupropion, sertraline, venlafaxine, treatment-resistant depression, symptom remission, antidepressant response, outpatients
- MeSH terms
- Venlafaxine Hydrochloride, Adult, Cyclohexanols, Delayed-Action Preparations, Major Depressive Disorder, Female, Humans, Male, Remission Induction, Time Factors, Bupropion, Treatment Failure, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.